Crestline Management LP Purchases New Stake in Immunocore Holdings plc (NASDAQ:IMCR)

Crestline Management LP acquired a new position in shares of Immunocore Holdings plc (NASDAQ:IMCR) in the 4th quarter, Holdings Channel.com reports. The firm acquired 24,960 shares of the company’s stock, valued at approximately $736,000.

Other large investors also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its position in shares of Immunocore by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after buying an additional 960 shares during the period. NEOS Investment Management LLC boosted its stake in Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after acquiring an additional 1,102 shares during the last quarter. Virtus ETF Advisers LLC grew its holdings in Immunocore by 39.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock worth $340,000 after acquiring an additional 3,238 shares during the period. XTX Topco Ltd raised its position in shares of Immunocore by 22.2% during the 4th quarter. XTX Topco Ltd now owns 18,896 shares of the company’s stock valued at $557,000 after acquiring an additional 3,437 shares during the last quarter. Finally, Barclays PLC lifted its stake in shares of Immunocore by 2,044.0% in the 4th quarter. Barclays PLC now owns 20,625 shares of the company’s stock valued at $608,000 after purchasing an additional 19,663 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Trading Down 4.7 %

Shares of NASDAQ:IMCR opened at $28.40 on Friday. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -29.89 and a beta of 0.75. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. Immunocore Holdings plc has a 12 month low of $23.15 and a 12 month high of $60.25. The company’s fifty day simple moving average is $28.81 and its 200 day simple moving average is $30.17.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.45. The firm had revenue of $125.13 million for the quarter, compared to the consensus estimate of $108.82 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company’s revenue for the quarter was up 33.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.49) EPS. As a group, research analysts forecast that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IMCR has been the subject of a number of recent analyst reports. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price objective on shares of Immunocore in a report on Friday, March 7th. Mizuho lowered their price target on Immunocore from $38.00 to $33.00 and set a “neutral” rating for the company in a research note on Monday, April 7th. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research note on Wednesday, March 12th. Oppenheimer increased their target price on shares of Immunocore from $85.00 to $86.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, JPMorgan Chase & Co. decreased their price target on shares of Immunocore from $54.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, April 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $58.13.

Insider Buying and Selling at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the purchase, the director now owns 2,144,060 shares of the company’s stock, valued at approximately $63,721,463.20. This represents a 60.40 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.40% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.